Wisp’s menopause consultation starts with a monthly access price and a promise of follow-up support. A reader browsing its wider menopause shop can also encounter vaginal prescriptions, skincare and nonprescription products. Preparing for the clinical conversation means separating the concern that needs assessment from the assortment of items displayed around it.
We reviewed Wisp’s official consultation, product and terms information on September 28, 2026. We did not submit health information, contact a provider or order medication. This review explains the published access and payment boundaries without assuming that a care-team membership, a prescription request and a pharmacy purchase are the same service.
Start with the consultation rather than the shop category
The menopause consultation page displays a starting price of $33 per month for the consult, follow-ups and monthly care-team access. It names estrogen treatment options but says prescribed medicines are paid for at a local pharmacy. The charge therefore should not be described as $33 for a complete supply of hormone therapy.
The broader menopause shop contains products with other purposes. Our hot-flash and sleep goals guide can help put the concern before the purchase category. A reader can ask what the assessment addresses and what happens if the clinician concludes that the desired product is not appropriate.
Confirm how the clinical exchange will happen
The consult offer establishes provider review and care-team access, but the available description does not guarantee a scheduled face-to-face video session of a particular length. We do not turn the word consultation into a promise of that format. The reviewed vaginal-product page separately describes possible follow-up by phone or secure chat when needed.
People wanting a reserved live conversation can compare MyMenopauseRx. Those comfortable with written contact may compare Alloy’s portal consultation. These links concern communication structure, not clinical quality. Before paying, the practical question is whether the service can provide the kind of exchange needed to explain the concern and receive a sufficiently clear answer.
A prescription remains conditional after payment
Wisp’s terms require consultation, a licensed practitioner’s assessment of appropriateness and a valid prescription before a prescription product can be obtained. They also describe platform eligibility for adults located in the United States. The menopause offer’s nationwide availability statement does not establish that a particular individual or requested medicine will qualify.
A reader can make uncertainty part of the request rather than trying to complete the intake as though approval were the only successful outcome. Our later-start conversation guide is relevant when timing and medical history complicate the question. An online purchase pathway does not eliminate the need to consider those circumstances with the responsible clinician.
Explain vaginal symptoms without assuming a systemic answer
Wisp’s separate estradiol product page concerns vaginal dryness and displays a starting $20 figure. That is a distinct offer from the $33 monthly menopause consultation. The page describes prescription transmission to a pharmacy while also using broader delivery language, so it does not establish one universal checkout and fulfillment arrangement.
Our vaginal-symptom visit guide helps the reader describe the issue before comparing those offers. FDA menopause information recognizes different symptom-treatment purposes. A lower displayed figure does not identify a suitable route, the final medication cost or what assessment would be needed for a concern that has not yet been explained.
Pharmacy payment should be discussed before the handoff
The terms distinguish fulfillment through a mail-order partner from sending a prescription to a selected local pharmacy. Under the local route, the patient obtains and pays for the medicine separately. Wisp’s menopause consultation specifically describes this local-pharmacy arrangement; a general shipping statement elsewhere should not override it.
The Pandia Health review offers another example of separating a clinical consultation from pharmacy services. A useful closing question is how an affordability or availability problem gets back to the prescriber. Sending the prescription on the same day does not mean the item is in stock, covered by insurance or already in the patient’s hands.
Understand recurring access and the refund boundary
Wisp’s terms describe recurring subscription charges and generally final sales, with refunds or replacements subject to the stated exceptions and discretion. We did not test cancellation or a refund request. The consultation’s monthly starting price does not explain every charge a reader might encounter across services, medicines and renewals.
It is reasonable to clarify which payment keeps care-team access active and what happens to that access if a subscription ends. That administrative question is separate from asking a clinician about an ongoing treatment. A complaint about billing, a request to stop a future charge and a new medical concern may need different responses even when they are sent through the same account.
Follow-up should address the question that remains
The consult page includes follow-ups in its offer but does not specify a single schedule or response deadline for every situation. A reader should leave the initial exchange knowing where to direct an unresolved concern and whether another type of appointment is needed. Monthly access is not evidence of continuous observation or emergency availability.
Our bleeding-history guide illustrates why a change should be described explicitly rather than buried in a request for another order. Wisp’s public pages establish a menopause-care pathway, but they do not show how a particular practitioner would handle that information. This assessment therefore ends with the documented responsibilities and unknowns, without ranking unobserved care or promising relief.
Read alongside the article
Sources & notes.
These sources provide provider descriptions or medical context. They do not replace an individual clinical assessment.
- Wisp: menopause consultation ↗Provider consultation offer; starting care price excludes local-pharmacy medicine; extracted eligibility FAQ incomplete · Checked 2026-09-28
- Wisp: menopause treatment shop ↗Provider category page; consult, local estrogen, cosmetic and nonprescription products kept distinct; wearable limits explicit · Checked 2026-09-28
- Wisp: terms of use ↗Platform legal terms; clinician/pharmacy roles and general subscription/refund provisions, not individualized legal advice · Checked 2026-09-28
- Wisp: estradiol vaginal cream ↗Provider local-estrogen product page; selected quantity, full charge and eligibility wording unresolved · Checked 2026-09-28
- FDA: Menopause ↗Current federal patient guidance; individualized benefits/risks and prevention limits, no class-wide labeling-change inference · Checked 2026-09-28